Secondary Logo

Journal Logo

Institutional members access full text with Ovid®

Humoral rejection in kidney transplantation: new concepts in diagnosis and treatment

Mauiyyedi, Shamilaa; Colvin, Robert B.b

Current Opinion in Nephrology and Hypertension: November 2002 - Volume 11 - Issue 6 - p 609-618
Dialysis and transplantation
Buy

Purpose of review Evidence from several transplant centers indicates that a substantial proportion of acute and chronic renal allograft rejection is caused by antibodies to donor antigens. Antibody-mediated injury arises despite potent anti-T cell pharmacological agents, and probably requires different therapy.

Recent findings Acute humoral rejection occurs in 20-30% of acute rejection cases, has a poorer prognosis than cellular rejection, and is refractory to conventional immunosuppressive therapy. C4d deposition in peritubular capillaries of renal allografts has been demonstrated to be a sensitive and diagnostic in-situ marker of acute humoral rejection that correlates strongly with the presence of circulating donor-specific antibodies. Biopsies with chronic allograft arteriopathy or glomerulopathy also have a high frequency of C4d deposition and donor-specific antibodies. The vessels of other organs, notably the heart, can also be targets of humoral rejection. New polyclonal C4d antibodies work in paraffin sections. Pitfalls in C4d staining have been identified and must be considered in the valid interpretation of results.

Summary As the histology is variable, the current diagnosis of humoral rejection in biopsies relies on the demonstration of C4d, a component of the classical complement pathway, in peritubular capillaries. The new classification of renal allograft rejection incorporates humoral and cellular mechanisms of injury, with the diagnostic criteria of each. This should prove useful in guiding clinical treatment, and stratifying drug trials, replacing obsolete terms such as ‘vascular rejection’. Specific therapeutic strategies for humoral rejection with controlled trials targeting the humoral limb of immunosuppression are needed.

aDepartment of Pathology, University of Texas-Houston, Health Sciences Center, Houston, Texas, USA; and bDepartment of Pathology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA

Correspondence to Robert B. Colvin, MD, Department of Pathology, Massachusetts General Hospital, 55 Fruit Street, Warren 225, Boston, MA 02114, USA. Tel: +1 617 726 2966; fax: +1 617 726 7533; e-mail: colvin@helix.mgh.harvard.edu

© 2002 Lippincott Williams & Wilkins, Inc.